Latest & greatest articles for breast cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on breast cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on breast cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for breast cancer

41. Ribociclib (Kisqali) - breast cancer

Ribociclib (Kisqali) - breast cancer 1 Published 11 November 2019 1 SMC2198 ribociclib 200mg film-coated tablets (Kisqali ® ) Novartis Pharmaceuticals UK Ltd 04 October 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following a full submission assessed under the end of life and orphan medicine process (...) ribociclib (Kisqali ® ) is accepted for restricted use within NHSScotland. Indication under review: for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with fulvestrant* as initial endocrine-based therapy, or in women who have received prior endocrine therapy. SMC restriction: women who have relapsed on or within 12 months of completing (neo) adjuvant endocrine therapy

2019 Scottish Medicines Consortium

42. Stage I Breast Cancer: Initial Workup and Surveillance for Local Recurrence and Distant Metastases in Asymptomatic Women.

Stage I Breast Cancer: Initial Workup and Surveillance for Local Recurrence and Distant Metastases in Asymptomatic Women. American College of Radiology End User License Agreement ACR Appropriateness Criteria is a registered trademark of the American College of Radiology. By accessing the ACR Appropriateness Criteria®, you expressly agree and consent to the terms and conditions as described at: http://www.acr.org/~/media/ACR/Documents/AppCriteria/TermsandConditions.pdf Personal use of material (...) Cancer American College of Radiology ACR Appropriateness Criteria ® Clinical Condition: Stage I Breast Cancer: Initial Workup and Surveillance for Local Recurrence and Distant Metastases in Asymptomatic Women Variant 1: Newly diagnosed. Initial workup. Rule out bone metastases. Radiologic Procedure Rating Comments RRL* FDG-PET/CT whole body 2 ???? Tc-99m bone scan whole body 1 ??? X-ray skeletal survey 1 ??? Rating Scale: 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually

2019 American College of Radiology

43. Combination Therapy for the Treatment of Adults with Any Stage Breast Cancer: Clinical Effectiveness and Guidelines

Combination Therapy for the Treatment of Adults with Any Stage Breast Cancer: Clinical Effectiveness and Guidelines Combination Therapy for the Treatment of Adults with Any Stage Breast Cancer: Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Combination Therapy for the Treatment of Adults with Any Stage Breast Cancer: Clinical Effectiveness and Guidelines Combination Therapy for the Treatment of Adults with Any Stage Breast Cancer: Clinical Effectiveness (...) and Guidelines Last updated: February 5, 2019 Project Number: RB1307-000 Product Line: Research Type: Devices and Systems Report Type: Summary of Abstracts Result type: Report Question What is the clinical effectiveness of combination therapy in adults with any stage of breast cancer? What are the evidence-based guidelines associated with the use of combination therapy in adults with any stage of breast cancer? Key Message Two systematic reviews (one with a meta-analysis), 15 non-randomized studies, and one

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

44. Abemaciclib for advanced or metastatic Breast Cancer – Details

Abemaciclib for advanced or metastatic Breast Cancer – Details Abemaciclib for advanced or metastatic Breast Cancer – Details | CADTH.ca Find the information you need Abemaciclib for advanced or metastatic Breast Cancer – Details Abemaciclib for advanced or metastatic Breast Cancer – Details Project Number pCODR 10161 Brand Name Verzenio Generic Name Abemaciclib Strength 50 mg, 100 mg, 150 mg and 200 mg Tumour Type Breast Indication Advanced or metastatic breast cancer Funding Request (...) For the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer: • In combination with an aromatase inhibitor in postmenopausal women as initial endocrine based therapy. • In combination with fulvestrant in women with disease progression following endocrine therapy. Pre- or perimenopausal women must also be treated with a gonadotropin-releasing hormone agonist. Review Status Notification to Implement Issued Pre Noc Submission Yes

2019 CADTH - Pan Canadian Oncology Drug Review

45. Telemammography for Breast Cancer Diagnosis: Clinical Utility, Cost-Effectiveness, and Guidelines

Telemammography for Breast Cancer Diagnosis: Clinical Utility, Cost-Effectiveness, and Guidelines Telemammography for Breast Cancer Diagnosis: Clinical Utility, Cost-Effectiveness, and Guidelines | CADTH.ca Find the information you need Telemammography for Breast Cancer Diagnosis: Clinical Utility, Cost-Effectiveness, and Guidelines Telemammography for Breast Cancer Diagnosis: Clinical Utility, Cost-Effectiveness, and Guidelines Last updated: August 27, 2019 Project Number: RB1389-000 Product (...) Line: Research Type: Devices and Systems Report Type: Summary of Abstracts Result type: Report Question What is the clinical utility of telemammography for the diagnosis of breast cancer? What is the cost-effectiveness of telemammography for the diagnosis of breast cancer? What are the evidence based guidelines regarding the use of telemammography for the diagnosis of breast cancer? Key Message No relevant health technology assessments, systematic reviews, meta-analyses, randomized-controlled

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

46. Kisqali for Advanced or Metastatic Breast Cancer – Details

Kisqali for Advanced or Metastatic Breast Cancer – Details Kisqali for Advanced or Metastatic Breast Cancer – Details | CADTH.ca Find the information you need Kisqali for Advanced or Metastatic Breast Cancer – Details Kisqali for Advanced or Metastatic Breast Cancer – Details Project Number pCODR 10194 Brand Name Kisqali Generic Name Ribociclib Tumour Type Breast Indication Advanced or Metastatic Breast Cancer Funding Request In combination with an aromatase inhibitor (AI) and a luteinizing (...) hormone releasing hormone (LHRH) agonist for the treatment of pre/peri- menopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, as initial endocrine-based therapy Review Status Under Review Pre Noc Submission Yes NOC Date Manufacturer Novartis Pharmaceuticals Canada Inc. Sponsor Novartis Pharmaceuticals Canada Inc. Submission Date August 26, 2019 Submission Deemed Complete September 10, 2019 Submission Type

2019 CADTH - Pan Canadian Oncology Drug Review

47. Atezolizumab (Tecentriq) for Advanced or Metastatic Triple-Negative Breast Cancer — Details

Atezolizumab (Tecentriq) for Advanced or Metastatic Triple-Negative Breast Cancer — Details Atezolizumab (Tecentriq) for Advanced or Metastatic Triple-Negative Breast Cancer — Details | CADTH.ca Find the information you need Atezolizumab (Tecentriq) for Advanced or Metastatic Triple-Negative Breast Cancer — Details Atezolizumab (Tecentriq) for Advanced or Metastatic Triple-Negative Breast Cancer — Details Project Number pCODR 10171 Brand Name Tecentriq Generic Name Atezolizumab Strength 840 mg (...) /14 mL & 1200 mg/20 mL Tumour Type Breast Indication Advanced or Metastatic Triple-Negative Breast Cancer (TNBC) Funding Request In combination with nab-paclitaxel for the treatment of adult patients with unresectable, locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumours express PD-L1, and who have not received prior chemotherapy for metastatic disease. Maintenance TECENTRIQ should be continued until disease progression or unacceptable toxicity. Review Status Open

2019 CADTH - Pan Canadian Oncology Drug Review

48. Nerlynx for Hormone Receptor-Positive Breast Cancer – Details

Nerlynx for Hormone Receptor-Positive Breast Cancer – Details Nerlynx for Hormone Receptor-Positive Breast Cancer – Details | CADTH.ca Find the information you need Nerlynx for Hormone Receptor-Positive Breast Cancer – Details Nerlynx for Hormone Receptor-Positive Breast Cancer – Details Project Number pCODR 10172 Brand Name Nerlynx Generic Name Neratinib Strength 40 mg Tumour Type Breast Indication Hormone Receptor-Positive Breast Cancer Funding Request For patients with HER2-positive, hormone (...) receptor-positive breast (HR-positive) cancer who have completed adjuvant trastuzumab-based therapy within the past 12 months Review Status Open for Feedback on Recommendation Pre Noc Submission Yes NOC Date July 16, 2019 Manufacturer Knight Therapeutics Inc. Sponsor Knight Therapeutics Inc. Submission Date April 18, 2019 Submission Deemed Complete May 3, 2019 Submission Type New Drug Prioritization Requested Stakeholder Input Deadline ‡ May 3, 2019 Check-point meeting July 4, 2019 pERC Meeting

2019 CADTH - Pan Canadian Oncology Drug Review

49. Ibrance (with Faslodex) for Advanced or Metastatic Breast Cancer – Details

Ibrance (with Faslodex) for Advanced or Metastatic Breast Cancer – Details Ibrance (with Faslodex) for Advanced or Metastatic Breast Cancer – Details | CADTH.ca Find the information you need Ibrance (with Faslodex) for Advanced or Metastatic Breast Cancer – Details Ibrance (with Faslodex) for Advanced or Metastatic Breast Cancer – Details Project Number pCODR 10150 Brand Name Ibrance (with Faslodex) Generic Name Palbociclib (with Fulvestrant) Strength 75 mg, 100 mg & 125 mg Tumour Type Breast (...) Indication Advanced or Metastatic Breast Cancer Funding Request In combination with fulvestrant for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer whose disease progressed after prior endocrine therapy, Pre- or perimenopausal women must also be treated with a luteinizing hormone releasing hormone (LHRH) agonist Review Status Notification to Implement Issued Pre Noc Submission No NOC Date May

2019 CADTH - Pan Canadian Oncology Drug Review

50. Trastuzumab Emtansine (Kadcyla) for Early Breast Cancer (EBC) — Details

Trastuzumab Emtansine (Kadcyla) for Early Breast Cancer (EBC) — Details Trastuzumab Emtansine (Kadcyla) for Early Breast Cancer (EBC) — Details | CADTH.ca Find the information you need Trastuzumab Emtansine (Kadcyla) for Early Breast Cancer (EBC) — Details Trastuzumab Emtansine (Kadcyla) for Early Breast Cancer (EBC) — Details Project Number pCODR 10182 Brand Name Kadcyla Generic Name Trastuzumab Emtansine Tumour Type Breast Indication Early Breast Cancer (EBC) Funding Request For the adjuvant (...) treatment of patients with HER2-positive early breast cancer, who have residual disease, after pre-operative systemic treatment. KADCYLA should be continued for 14 cycles or until disease progression or unacceptable toxicity. If KADCYLA is discontinued in the event of toxicity, treatment with trastuzumab may be continued to complete one year of HER2-directed therapy. Review Status Under Review Pre Noc Submission Yes NOC Date Manufacturer Hoffmann-La Roche Limited Sponsor Hoffmann-La Roche Limited

2019 CADTH - Pan Canadian Oncology Drug Review

51. Kisqali (with Fulvestrant) for Advanced or Metastatic Breast Cancer – Details

Kisqali (with Fulvestrant) for Advanced or Metastatic Breast Cancer – Details Kisqali (with Fulvestrant) for Advanced or Metastatic Breast Cancer – Details | CADTH.ca Find the information you need Kisqali (with Fulvestrant) for Advanced or Metastatic Breast Cancer – Details Kisqali (with Fulvestrant) for Advanced or Metastatic Breast Cancer – Details Project Number pCODR 10195 Brand Name Kisqali Generic Name Ribociclib with Fulvestrant Tumour Type Breast Indication Advanced or Metastatic Breast (...) Cancer Funding Request In combination with fulvestrant for the treatment of postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer, as initial therapy or following disease progression on endocrine therapy Review Status Under Review Pre Noc Submission Yes NOC Date Manufacturer Novartis Pharmaceuticals Canada Inc. Sponsor Novartis Pharmaceuticals Canada Inc. Submission Date August 26, 2019 Submission Deemed Complete September 10, 2019 Submission Type New Indication

2019 CADTH - Pan Canadian Oncology Drug Review

52. Ogivri for Early Breast Cancer / Metastatic Breast Cancer / Metastatic Gastric Cancer Biosimilar – Details

Ogivri for Early Breast Cancer / Metastatic Breast Cancer / Metastatic Gastric Cancer Biosimilar – Details Ogivri for Early Breast Cancer / Metastatic Breast Cancer / Metastatic Gastric Cancer Biosimilar – Details | CADTH.ca Find the information you need Ogivri for Early Breast Cancer / Metastatic Breast Cancer / Metastatic Gastric Cancer Biosimilar – Details Ogivri for Early Breast Cancer / Metastatic Breast Cancer / Metastatic Gastric Cancer Biosimilar – Details Project Number pCODR 10169 (...) Brand Name Ogivri Generic Name Trastuzumab Strength 150 mg/vial and 440 mg/vial Tumour Type Breast / Gastrointestinal Indication Early Breast Cancer / Metastatic Breast Cancer / Metastatic Gastric Cancer Biosimilar Funding Request For the treatment of patients with early stage breast cancer with ECOG 0-1 status, whose tumours overexpress HER2, following surgery and after chemotherapy, following adjuvant chemotherapy consisting of doxorubicin and cyclophosphamide, in combination with paclitaxel

2019 CADTH - Pan Canadian Oncology Drug Review

53. Trastuzumab for Breast and Gastric Cancer Biosimilar – Details

Trastuzumab for Breast and Gastric Cancer Biosimilar – Details Trastuzumab for Breast and Gastric Cancer Biosimilar – Details | CADTH.ca Find the information you need Trastuzumab for Breast and Gastric Cancer Biosimilar – Details Trastuzumab for Breast and Gastric Cancer Biosimilar – Details Project Number pCODR 10160 Brand Name TBD Generic Name Trastuzumab Strength Tumour Type Breast & Gastrointestinal Indication Breast and Gastric Cancer Biosimilar Funding Request Breast and Gastric Cancer

2019 CADTH - Pan Canadian Oncology Drug Review

54. Preoperative Seed Placement for Breast Cancer Surgery: Clinical Effectiveness, Cost-Effectiveness, and Guidelines

Preoperative Seed Placement for Breast Cancer Surgery: Clinical Effectiveness, Cost-Effectiveness, and Guidelines Preoperative Seed Placement for Breast Cancer Surgery: Clinical Effectiveness, Cost-Effectiveness, and Guidelines | CADTH.ca Find the information you need Preoperative Seed Placement for Breast Cancer Surgery: Clinical Effectiveness, Cost-Effectiveness, and Guidelines Preoperative Seed Placement for Breast Cancer Surgery: Clinical Effectiveness, Cost-Effectiveness, and Guidelines (...) Last updated: April 1, 2019 Project Number: RB1319-000 Product Line: Research Type: Devices and Systems Report Type: Summary of Abstracts Result type: Report Question What is the clinical effectiveness of preoperative seed placement for patients undergoing surgery for breast cancer? What is the cost-effectiveness of preoperative seed placement for patients undergoing surgery for breast cancer? What are the evidence-based guidelines regarding methods of preoperative tumor localization for patient

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

55. Gene Expression Profiling Tests for Breast Cancer: A Rapid Qualitative Review

Gene Expression Profiling Tests for Breast Cancer: A Rapid Qualitative Review Gene Expression Profiling Tests for Breast Cancer: A Rapid Qualitative Review | CADTH.ca Find the information you need Gene Expression Profiling Tests for Breast Cancer: A Rapid Qualitative Review Gene Expression Profiling Tests for Breast Cancer: A Rapid Qualitative Review Last updated: April 18, 2019 Project Number: RC1099-000 Product Line: Research Type: Devices and Systems Report Type: Summary with Critical (...) Appraisal Result type: Report Question What are patients’ and clinicians’ expectations of gene expression profiling tests for breast cancer? How do patients and clinicians understand, communicate, and make decisions to undergo gene expression profiling testing for breast cancer? How do patients and clinicians understand, communicate and make decisions based on the results? How does the option, or not, of gene expression profile testing help to shape patients’, and clinicians’ experiences and perceptions

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

56. Intraoperative Mammography for Breast Cancer Surgery: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines

Intraoperative Mammography for Breast Cancer Surgery: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines Intraoperative Mammography for Breast Cancer Surgery: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines | CADTH.ca Find the information you need Intraoperative Mammography for Breast Cancer Surgery: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines Intraoperative Mammography for Breast Cancer Surgery: A Review of Clinical (...) Effectiveness, Cost-Effectiveness, and Guidelines Last updated: April 22, 2019 Project Number: RC1102-000 Product Line: Research Type: Devices and Systems Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of intraoperative imaging with mammography for breast cancer surgery? What is the cost-effectiveness of intraoperative imaging with mammography for breast cancer surgery? What are the evidence-based guidelines regarding intraoperative imaging

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

57. Sentinel Lymph Node Biopsy for the Management of Breast Cancer: A Review of Guidelines

Sentinel Lymph Node Biopsy for the Management of Breast Cancer: A Review of Guidelines Sentinel Lymph Node Biopsy for the Management of Breast Cancer: A Review of Guidelines | CADTH.ca Find the information you need Sentinel Lymph Node Biopsy for the Management of Breast Cancer: A Review of Guidelines Sentinel Lymph Node Biopsy for the Management of Breast Cancer: A Review of Guidelines Last updated: April 24, 2019 Project Number: RC1103-000 Product Line: Research Type: Devices and Systems (...) Report Type: Summary with Critical Appraisal Result type: Report Question What are the evidence-based guidelines regarding methods for sentinel lymph node biopsy for the management of breast cancer? Key Message Five evidence-based guidelines were identified. SLNB is recommended for axillary staging for patients with early-stage or invasive breast cancer without clinically or pathologically positive lymph nodes. SLNB is recommended in patients with ductal carcinoma in situ (DCIS) when mastectomy

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

58. Digital Tomosynthesis for the Screening and Diagnosis of Breast Cancer: Diagnostic Accuracy, Cost-Effectiveness, and Guidelines

Digital Tomosynthesis for the Screening and Diagnosis of Breast Cancer: Diagnostic Accuracy, Cost-Effectiveness, and Guidelines Digital Tomosynthesis for the Screening and Diagnosis of Breast Cancer: Diagnostic Accuracy, Cost-Effectiveness, and Guidelines | CADTH.ca Find the information you need Digital Tomosynthesis for the Screening and Diagnosis of Breast Cancer: Diagnostic Accuracy, Cost-Effectiveness, and Guidelines Digital Tomosynthesis for the Screening and Diagnosis of Breast Cancer (...) : Diagnostic Accuracy, Cost-Effectiveness, and Guidelines Last updated: June 11, 2019 Project Number: RB1351-000 Product Line: Research Type: Devices and Systems Report Type: Summary of Abstracts Result type: Report Question What is the clinical effectiveness of 3D digital tomosynthesis with or without 2D mammography compared with 2D mammography alone for breast cancer diagnosis? What is the diagnostic accuracy of 3D digital tomosynthesis with or without 2D mammography compared with 2D mammography alone

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

59. Rural Breast Cancer Surgery Programs: A Rapid Qualitative Review

Rural Breast Cancer Surgery Programs: A Rapid Qualitative Review Rural Breast Cancer Surgery Programs: A Rapid Qualitative Review | CADTH.ca Find the information you need Rural Breast Cancer Surgery Programs: A Rapid Qualitative Review Rural Breast Cancer Surgery Programs: A Rapid Qualitative Review Last updated: May 3, 2019 Project Number: RC1104-000 Product Line: Research Type: Devices and Systems Report Type: Summary with Critical Appraisal Result type: Report Question What (...) are the experiences and perspectives of breast cancer patients, their caregivers and their health care providers with respect to breast cancer surgical care in rural areas? To ensure the relevance of the analysis to the objectives of the primary research question, a secondary set of research questions was explored during data extraction and analysis:a) How do people with breast cancer, and their families, experience travelling for breast cancer surgical care?b) What is the meaning and impact of receiving breast

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

60. Sample Selection for Biomarker Testing in Adults with Breast Cancer: Guidelines

Sample Selection for Biomarker Testing in Adults with Breast Cancer: Guidelines Sample Selection for Biomarker Testing in Adults with Breast Cancer: Guidelines | CADTH.ca Find the information you need Sample Selection for Biomarker Testing in Adults with Breast Cancer: Guidelines Sample Selection for Biomarker Testing in Adults with Breast Cancer: Guidelines Last updated: February 6, 2019 Project Number: RB1305-000 Product Line: Research Type: Devices and Systems Report Type: Summary (...) of Abstracts Result type: Report Question What are the evidence-based guidelines regarding sample selection for biomarker testing to inform treatment decisions in adults with breast cancer? Key Message Four evidence-based guidelines were identified regarding sample selection for biomarker testing in adults with breast cancer. Files Rapid Response Summary of Abstracts Published : February 6, 2019 Related Content Follow us: © 2019 Canadian Agency for Drugs and Technologies in Health Get our newsletter:

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review